The Pfizer-BioNTech<unk> is an mRNA based<unk>  which is approved in the United States to prevent symptomatic<unk> -19 infection. The Pfizer-BioNTech was the first<unk> to be approved for distribution in the United States, and it was granted Emergency Use Authorization by the United States Food and Drug Administration (FDA) on 11 December 2020.
The approved<unk>  dosing regimen is an intramuscular injection given as two doses, 30 μg each, administered 21 days apart. The<unk>  is approved for individuals 16 years of age and older.
The<unk>  is intended to prevent the<unk> -19 illness, which is caused by  the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Pfizer-BioNTech<unk>  targets the SARS-CoV-2 spike glycoprotein (S).
COVID-19 Vaccine 
Isolation precautions
HIV post-exposure prophylaxis
United States Antibiogram
Vaccination schedule
HIV testing 
Post exposure prophylaxis antibiotics
Crotalidae polyvalent immune Fab 